Hydrophilic β-conglycinin Peptide Reduces Hepatic Triglyceride Accumulation in Obese Model OLETF Rats

Wanezaki, Satoshi; Saito, Shintaro; Inoue, Nao; Tachibana, Nobuhiko; Yanagita, Teruyoshi; Nagao, Koji

doi:10.3136/fstr.26.797

Cited by 1 publication

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, higher lunasin concentration in dietary supplements was associated with higher antioxidant capacity [21]. Glycinin and β-conglycinin make up most of the protein content of soybean, and β-conglycinin in particular had been shown to be able to reduce obesity and LDL cholesterol, as well as inhibiting lipid accumulation and lowering inflammation [4,[22][23][24]. Peptides from soybean were also found to be able to reduce intestinal inflammation through maintenance of intestinal mucosal integrity and suppression pro-inflammatory biomarkers [25][26][27].…”

Section: Discussionmentioning

confidence: 99%

Soybean (Glycine max) INFOGEST Colonic Digests Attenuated Inflammatory Responses Based on Protein Profiles of Different Varieties

Kusumah

Castañeda-Reyes

Bringe

et al. 2023

IJMS

View full text Add to dashboard Cite

Soybean compounds have been established to modulate inflammation, but less is known about how whole soybean compositions work together after digestion. The objective was to evaluate and compare the anti-inflammatory responses of different soybean varieties under simulated gastrointestinal digestion, with additional consideration of the glycinin:β-conglycinin ratio (GBR). Soybean colonic digests (SCD) inhibited cyclooxygenase (COX)-2 (25–82%), 5-lipoxidase (LOX) (18–35%), and inducible nitric oxide (iNOS) (8–61%). Varieties 88, GN3, and 93 were the most effective inhibitors. SCD (1 mg/mL) of varieties 81 and GN1 significantly (p < 0.05) reduced nitrite production by 44 and 47%, respectively, compared to lipopolysaccharide (LPS)-stimulated macrophages. SCD effectively reduced pro-inflammatory cytokine interleukin (IL)-6 (50 and 80% for 96 and GN1, respectively). Western blot results showed a decrease in the expression of iNOS, p65, and p50. The GBR was in the range of 0.05–1.57. Higher ratio correlated with higher production of IL-1β (r = 0.44) and tumor necrosis factor-alpha (TNF-α, r = 0.56). Inflammatory microarray results showed a significant decrease in expression of markers granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-6 in cells treated with GN1 SCD compared to LPS. The results suggested that SCD exerted its anti-inflammatory potential through nuclear factor kappa B (NF-κΒ) pathway inhibition by decreasing the levels of NF-κB-dependent cytokines and subunits, and inhibition of pro-inflammatory enzyme activity.

show abstract